Initial treatment for prolactinoma is usually conservative with dopamine agonists. However,
the duration of treatment is often lifelong and can be associated with significant side effects …

Introduction Prolactinoma account to the most common pituitary adenomas and current
therapy regime constitutes of dopamine agonist therapy (DA) and surgery in selected cases …

Background Endoscopic transsphenoidal surgery (ETSS) for prolactinoma is reserved for
dopamine agonist (DA) resistance, intolerance, or apoplexy. High remission (overall 67 …

Purpose To describe care trajectories in patients with prolactinoma, aiming to clarify the
rationale for surgery. Methods Retrospective observational cohort study of consecutive …

Purpose To evaluate patients with prolactinoma treated surgically in a time when elective
prolactinoma surgery became routine in our center, using a comprehensive outcome set …

Background The optimal therapeutic approach for cystic prolactinomas remains unclear.
This study aimed to evaluate the remission rates of prolactinoma patients after surgical …

Introduction. Giant prolactinoma (GP) is a rare pituitary lactotropic cell tumor larger than 4 cm
in its widest dimension, and is less likely than a smaller prolactinoma to achieve prolactin …

Objective Calcification in pituitary adenomas is a rare occurrence and its differential
diagnosis typically includes other sellar masses. Common calcifications in pituitary …

Objective Most patients with microprolactinomas require lifetime treatment with a dopamine
agonist. Many patients in our center have sought endoscopic transsphenoidal surgery as an …

Objective Pediatric pituitary adenomas are rare lesions and account for approximately 3% of
all supratentorial tumors in children. There is a paucity of reports on endoscopic …